FDA approves Regeneron’s Libtayo and chemotherapy combination for NSCLC

Press/Media

Period	9 Nov 2022

Media coverage

Title	FDA approves Regeneron’s Libtayo and chemotherapy combination for NSCLC
Media name/outlet	Pharmaceutical Technology
Country/Territory	United States
Date	9/11/22
URL	ct.moreover.com/?a=49211200249&p=1gw&v=1&x=0WUEevLHAAmBa729tNnX9A
Persons	Israel Lowy,